000			02155nam a2200241Ia 4500
003			NULRC
005			20250520094925.0
008			250520s9999 xx 000 0 und d
020			_a9780195067385
040			_cNULRC
050			_aRC 271.C5 .P73 1994
100			_aPratt, William B. _eauthor
245		4	_aThe anticancer drugs / _cWilliam B. Pratt [and three others].
250			_aSecond edition.
260			_aNew York : _bOxford University Press, _cc1994
300			_aviii, 352 pages : _billustrations ; _c26 cm.
504			_aIncludes bibliographical references and index.
505			_aPrinciples of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment. (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs.
520			_aThis is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs.
650			_aCANCER -- CHEMOTHERAPY
700			_aRuddon, Raymond W. ;Ensminger, William D. ;Maybaum, Jonathan _eco-author;co-author;co-author
942			_2lcc _cBK
999			_c6358 _d6358